Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Advair: A Big Generic Opportunity And A Big Question Mark In 2017

Dec 29 2016

• By Jessica Merrill

Biopharma In Perspective 2016-2017

Related Content

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

Mylan Confident On Advair Generic First-Round Approval

Aug 10 2016

Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World

Oct 26 2016

Related Companies

GSK plc

Viatris Inc.

Hikma Pharmaceuticals plc

AstraZeneca PLC

Teva Pharmaceutical Industries Ltd.

Novartis AG

Takeda Pharmaceutical Co. Ltd.

Gilead Sciences, Inc.

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

Generic Drugs Commercial Respiratory

More from Respiratory

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window